Effect of Soy Protein Containing Isoflavones on Cognitive Function, Bone Mineral Density, and Plasma Lipids in Postmenopausal Women

Kreijkamp-Kaspers, Sanne; Kok, Linda; Grobbee, Diederick E.; Haan, Edward H.F. de; Alemán, André; Lampe, Johanna W.; Schouw, Yvonne T. van der

doi:10.1001/jama.292.1.65

Cited by 386 publications

(272 citation statements)

References 55 publications

Supporting

Mentioning

241

Contrasting

Unclassified

Order By: Relevance

“…Our results show no significant changes in BALP. In the selected trials, only two trials indicated significant increase in BALP after phytoestrogens consumption (Morabito et al 2002;Atkinson et al 2004), and the remainder could not find any valuable alteration in serum concentration of BALP Arjmandi et al 2003;Ye et al 2006;Kreijkamp-Kaspers et al 2004). Morabito et al (2002) and Atkinson et al (2004) examined the dose as 54 mg and 43.5 mg of phytoestrogens, respectively, in 1 year.…”

Section: Discussionmentioning

confidence: 99%

“…The summary effect size and effect size for weighted mean difference for BALP for all reported data in different duration of time for follow-up and all doses in six trials Morabito et al 2002;Atkinson et al 2004;Arjmandi et al 2003;Ye et al 2006;Kreijkamp-Kaspers et al 2004) were 0.333747 (95% CI=−0.052381 to 0.719876) and 0.035662 (95% CI=−0.070331 to 0.141655), respectively, a non-significant results (P=0.0902, Fig. 4a and P=0.5096, Fig.…”

Section: Efficacy Of Phytoestrogens Comparing To Placebo In Balpmentioning

confidence: 91%

“…Assessment of trial quality Jadad score, which indicates the potentiality of the studies based on their description of randomization, blinding, and dropouts (withdrawals), was used to assess the methodological quality of trials (Uesugi et al 2002Yamori et al 2002;Dalais et al 2003;Morabito et al 2002;Atkinson et al 2004;Arjmandi et al 2003;Ye et al 2006;Zhang et al 2007;Albertazzi et al 2005;Kreijkamp-Kaspers et al 2004). The quality scale ranges from 0 to 5 points with a low-quality report of score 2 or less and a high-quality report of score at least 3.…”

Section: Data Sourcesmentioning

confidence: 99%

See 2 more Smart Citations

Prevention of bone resorption by intake of phytoestrogens in postmenopausal women: a meta-analysis

Salari

Nikfar

Abdollahi

2010

AGE

View full text Add to dashboard Cite

Phytoestrogens as selective estrogen receptor modulators like compounds may consider as a therapeutic option in osteoporosis. In this regard, the effect of phytoestrogens on bone biomarkers was examined in several trials which their results are controversial. We aimed this meta-analysis to evaluate the net effect of phytoestrogens on bone markers. A thorough search was conducted from 2000 to 2010 in English articles. All randomized clinical trials were reviewed, and finally, 11 eligible randomized clinical trials were selected for meta-analysis. Totally 1,252 postmenopausal women were enrolled in the study by considering the changes of pyridinoline (Pyd), desoxypyridinoline (Dpyd), bone alkaline phosphatase, and osteocalcin concentrations in urine and serum after phytoestrogens consumption. The urine Pyd and Dpyd levels decreased significantly in phytoestrogens consumers. Effect size and effect size for weighted mean difference of urine Pyd levels showed −1.229171 (95% confidence interval (CI)=−1.927639 to −0.530703) and −9.780623 (95% CI=−14.240401 to −5.320845), respectively, a significant results in comparison to control group and significant results for Dpyd −0.520132 (95% CI=−0.871988 to −0.168275) and −0.818582 (95% CI=−1.247758 to −0.389407), respectively. Metaanalysis indicates that phytoestrogens intake can prevent bone resorption, but its benefits on bone formation are not significant. This favorable effect

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Efficacy Of Phytoestrogens Comparing To Placebo In Balpmentioning

confidence: 91%

Section: Data Sourcesmentioning

confidence: 99%

See 1 more Smart Citation

Prevention of bone resorption by intake of phytoestrogens in postmenopausal women: a meta-analysis

Salari

Nikfar

Abdollahi

2010

AGE

View full text Add to dashboard Cite

show abstract

“…Current guidelines do not support isoflavones as a treatment for osteoporosis (Brown & Josse 2002). In summary, soy isoflavones induce either positive effects (Potter et al 1998;Alekel et al 2000;Morabito et al 2002;Uesugi et al 2002;Yamori et al 2002;Chen et al 2003b;Kreijkamp-Kaspers et al 2004;Mori et al 2004;Ye et al 2006) or no effects Arjmandi et al 2005) on bone metabolism in pre-menopausal and postmenopausal women. To our knowledge, no human feeding intervention studies have reported any negative effects of soy isoflavone consumption on bone metabolism.…”

Section: Feeding Intervention Trials In Humansmentioning

confidence: 98%

Functional Foods and Bone Health: Where are we at?

Ward

Lau

Kaludjerovic

et al. 2010

Functional Food Product Development

View full text Add to dashboard Cite

“…Six interventional studies have examined the effects of dietary iso fl avones on bone, and equol levels were determined. Kreijkamp-Kaspers et al [ 26 ] carried out a 12-month double-blind, randomized, placebo-controlled trial in 202 postmenopausal Dutch women (18 years past menopause) receiving 99 mg iso fl avones/day (41 mg daidzein) versus placebo. Equol producer status was de fi ned as a plasma equol concentration >83 nmol/L (approximately 20 ng/mL).…”

Section: S-equol-producing Status and Osteoporosismentioning

confidence: 99%

S-equol, a Natural Metabolite of Soy Daidzein, for the Treatment of Menopausal Symptoms and Osteoporosis in Postmenopausal Women

Jackson¹,

Greiwe²,

Schwen³

2013

Nutrition and Diet in Menopause

View full text Add to dashboard Cite

Key PointsS-equol is a potent, nonhormonal, nonsteroidal estrogen receptor • b agonist. S-equol is produced by the gut biotransformation of soy daidzein, an iso fl avone present in soy.• Individuals, particularly Asians, who are equol producers have fewer menopausal symptoms, • osteoporosis, diseases of the prostate, and cardiovascular diseases. A soy-derived dietary supplement containing 10 mg S-equol has been shown to reduce menopausal • symptoms and improve bone mineral density in postmenopausal women. A clinical study in men and women with doses of S-equol up to 320 mg/day demonstrated that the • compound has an excellent safety and pharmacokinetic pro fi le. IntroductionIn 2002 the results of the Women's Health Initiative (WHI) were published [ 1 ] . Surprisingly, postmenopausal women on hormone therapy (HT), Premarin ® (0.625 mg/day) plus medroxy-progesterone (2.5 mg/day), had signi fi cantly increased cardiovascular diseases, invasive breast cancer, stroke, and venous thromboembolism compared to the placebo group. The women on HT did have fewer hip fractures and there was a reduced incidence of colorectal cancer. Nonetheless, the fi ndings of WHI have had a major impact on women's health. Women do not want HT as re fl ected in the reduced prescriptions for products containing estrogens, and as a result, the incidence of hip fractures has increased by 55 % since 2002 [ 2 ] . As an alternative to HT, many women have resorted to nonhormonal therapies for the treatment of menopausal symptoms, including antidepressants, herbal extracts, soy extracts, and soy iso fl avones, also referred to as phytoestrogens [3][4][5][6] . It is well known that Japanese people consume large amounts of soy products and have fewer chronic diseases compared to Caucasians. Adlercreutz et al. [ 7 ] proposed that Japanese women have fewer menopausal symptoms based on their soy intake. The fi rst report on the consumption of soy products and the incidence of hot fl ashes was by Nagata et al., 2001 [ 8 ] . In this study, a questionnaire was used to measure an individual's intake of soy foods. The tertiles for soy intake were low (44.5 g/day), middle (75.2 g/day), and high (115.9 g/day); the intake of total iso fl avones was 20.5, 32.8, and 50.8 mg/day, respectively. A decrease in the hazard ratio for hot fl ashes was directly related to soy and total iso fl avone intake ( p < 0.005).Since these early fi ndings, many controlled clinical studies have been carried out with soy and soy iso fl avones to alleviate vasomotor symptoms (VMS) in menopausal women (for review, see [9][10][11] ). The results of meta-analysis are for the most part inconclusive as to the clinical bene fi t of soy and soy extracts. For many studies, the sample size was too small and the duration of the study was too short (<4-6 weeks) to show a statistical difference between the treated and placebo groups. If the frequency of hot fl ashes was the primary end point, there was little or no response to soy iso fl avone extracts in women who experienced four or fewer hot...

show abstract

Effect of Soy Protein Containing Isoflavones on Cognitive Function, Bone Mineral Density, and Plasma Lipids in Postmenopausal Women

Cited by 386 publications

References 55 publications

Prevention of bone resorption by intake of phytoestrogens in postmenopausal women: a meta-analysis

Prevention of bone resorption by intake of phytoestrogens in postmenopausal women: a meta-analysis

Functional Foods and Bone Health: Where are we at?

S-equol, a Natural Metabolite of Soy Daidzein, for the Treatment of Menopausal Symptoms and Osteoporosis in Postmenopausal Women

Contact Info

Product

Resources

About